Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.
Di Caro V, Cho E, Thiel J, Lizama BN, Koel-Simmelink MJA, Pandey K, Duong D, Seyfried NT, Grundman M, Teunissen CE, Zetterberg H, Blennow K, Caggiano AO, Hamby ME
Alzheimer's research & therapy 2026